Similar articles

• The Role of Pioglitazone in the Management of Nonalcoholic Steatohepatitis: Are We There Yet?

  Yee HF Jr. Yee HF Jr. JAMA Intern Med. 2017 May 1;177(5):640-641. doi: 10.1001/jamainternmed.2016.9669. JAMA Intern Med. 2017. PMID: 28241265 No abstract available.
• Pioglitazone for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes.

  [No authors listed] [No authors listed] Ann Intern Med. 2016 Sep 6;165(5). doi: 10.7326/P16-9018. Epub 2016 Jun 21. Ann Intern Med. 2016. PMID: 27322943 No abstract available.
• Letter: clinical response to pioglitazone in nonalcoholic steatohepatitis [NASH] treatment-use of pharmacokinetic surrogate.

  Srinivas NR. Srinivas NR. Aliment Pharmacol Ther. 2017 Aug;46(4):470-471. doi: 10.1111/apt.14169. Aliment Pharmacol Ther. 2017. PMID: 28707804 No abstract available.
• Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

  Corey KE, Rinella ME. Corey KE, et al. Dig Dis Sci. 2016 May;61(5):1387-97. doi: 10.1007/s10620-016-4083-8. Epub 2016 Mar 4. Dig Dis Sci. 2016. PMID: 26942734 Free PMC article. Review.
• The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.

  Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C. Athyros VG, et al. Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4. Metabolism. 2017. PMID: 28521870 Review.